胆管癌与肝细胞癌中癌相关循环大细胞外囊泡
该研究采用荧光激活细胞扫描检测血清中AnnexinV+ EpCAM+ CD147+和AnnexinV+ EpCAM+ ASGPR1+肿瘤相关微粒,共纳入172例肝癌(肝细胞癌或胆管癌)、54例无肝脏肿瘤的肝硬化和202例对照。结果显示AnnexinV+ EpCAM+ ASGPR1+ taMPs可区分肝脏恶性肿瘤与肝硬化及非肝脏肿瘤,R0切除后7天下降,ROC及预测值>78%。
要点
- AnnexinV+ EpCAM+ CD147+ taMPs在肝细胞癌和胆管癌中升高。
- AnnexinV+ EpCAM+ ASGPR1+ taMPs可区分肝脏恶性肿瘤与肝硬化及非肝脏肿瘤。
- R0切除后7天AnnexinV+ EpCAM+ ASGPR1+ taMPs下降,ROC及预测值>78%。
核心结论
- AnnexinV+ EpCAM+ ASGPR1+ taMPs是肝细胞癌和胆管癌液体活检的新型生物标志物,可无创评估晚期肝病患者中这些癌症的存在及可能范围。
研究设计与样本
- 采用荧光激活细胞扫描检测患者血清中肿瘤相关微粒群体,共纳入172例肝癌(肝细胞癌或胆管癌)、54例无肝脏肿瘤的肝硬化和202例对照。
主要发现
- AnnexinV+ EpCAM+ CD147+ taMPs在肝细胞癌和胆管癌中升高。
- AnnexinV+ EpCAM+ ASGPR1+ CD133+ taMPs可区分肝脏恶性肿瘤(肝细胞癌或胆管癌)与无肿瘤个体及携带其他非肝脏癌症的患者。
- AnnexinV+ EpCAM+ ASGPR1+ taMPs在携带肝癌患者中较无任何可检测肝脏恶性肿瘤的肝硬化患者升高。
- 成功检测到的最小癌症尺寸范围为11-15mm。
- 根治性R0肿瘤切除后7天AnnexinV+ EpCAM+ ASGPR1+ taMPs下降,提示与肿瘤存在密切关联。
关键数值与推荐
- ROC值、灵敏度/特异度评分及阳性/阴性预测值(>78%)提示AnnexinV+ EpCAM+ ASGPR1+ taMPs具有较强诊断准确性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Large extracellular vesicles, specifically AnnexinV+ EpCAM+ CD147+ tumour-associated microparticles (taMPs), facilitate the detection of colorectal carcinoma (CRC), non-small cell lung carcinoma (NSCLC) as well as pancreas carcinoma (PaCa). Here we assess the diagnostic value of taMPs for detection and monitoring of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Specifically, the aim of this study was to differentiate liver taMPs from other cancer taMPs, such as CRC and NSCLC. METHODS: Fluorescence-activated cell scanning (FACS) was applied to detect various taMP populations in patients' sera that were associated with the presence of a tumour (AnnexinV+ EpCAM+ CD147+ taMPs) or could discriminate between cirrhosis (due to HCV or HBV) and liver cancers (AnnexinV+ EpCAM+ ASGPR1+ taMPs). In total 172 patients with liver cancer (HCC or CCA), 54 with cirrhosis and no liver neoplasia, and 202 control subjects were enrolled. RESULTS: The results indicate that AnnexinV+ EpCAM+ CD147+ taMPs were elevated in HCC and CCA. Furthermore, AnnexinV+ EpCAM+ ASGPR1+ CD133+ taMPs allowed the distinction of liver malignancies (HCC or CCA) and cirrhosis from tumour-free individuals and, more importantly, from patients carrying other non-liver cancers. In addition, AnnexinV+ EpCAM+ ASGPR1+ taMPs were increased in liver cancer-bearing patients compared to patients with cirrhosis that lacked any detectable liver malignancy. The smallest sizes of successfully detected cancers were ranging between 11-15mm. AnnexinV+ EpCAM+ ASGPR1+ taMPs decreased at 7days after curative R0 tumour resection suggesting close correlations with tumour presence. ROC values, sensitivity/specificity scores and positive/negative predictive values (>78%) indicated a potent diagnostic accuracy of AnnexinV+ EpCAM+ ASGPR1+ taMPs. CONCLUSION: These data provide strong evidence that AnnexinV+ EpCAM+ ASGPR1+ taMPs are a novel biomarker of HCC and CCA liquid biopsy that permit a non-invasive assessment of the presence and possible extent of these cancers in patients with advanced liver diseases. LAY SUMMARY: Microparticles (MPs) are small vesicles that bleb from the membrane of every cell, including cancer cells, and are released to circulate in the bloodstream. Since their surface composition is similar to the surface of their underlying parental cell, MPs from the bloodstream can be isolated and by screening their surface components, the presence of their parental cells can be identified. This way, it was possible to detect and discriminate between patients bearing liver cancer and chronic liver cirrhosis.
引用
- Julich-Haertel H, Urban SK, Krawczyk M, et al. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol. 2017. PMID: 28267620. doi:10.1016/j.jhep.2017.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。